This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. This article delves into India’s growing importance in generic drug API manufacturing, highlighting the key factors contributing to its success and the challenges it faces.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs.
Threes still company in the world of pharmacy benefit managers. Below, we break down the latest market share data from Drug Channels Institute (DCI), explore the developments driving these changes, and examine what they signal for the future of the PBM landscape. Pharmacies and Pharmacy Benefit Managers ends today (3/31/25)!
Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute. Read on for details and my commentary below.
Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. d/b/a Drug Channels Institute.
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacymarket continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialty pharmacy trends.
Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment. The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions.
Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. How will the most consequential change in federal drug pricing policy affect the largest pharmacies and PBMs? to 1:30 p.m.
In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. d/b/a Drug Channels Institute.
Next week, Drug Channels Institute will release our 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. The largest 15 pharmacies accounted for more than 75% of total dispensing revenues from retail, mail, long-term care, and specialty pharmacies.
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S. All rights reserved.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.
On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. drug pricing, reimbursement, and dispensing system. we highlight potential implications of the IRA for the drug channel. d/b/a Drug Channels Institute. In Subsection 12.5.1.,
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Analyzes Impact of Inflation Reduction Act on U.S. d/b/a Drug Channels Institute.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Next week, Drug Channels Institute (DCI) will release our 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. All rights reserved.
This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. But what exactly is pharmacognosy, and how does it relate to the complex world of drug patents? This approach has led to the discovery of numerous potential drug candidates.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. It is part of The Drug Channels 2025 Video Webinar Series.
Three is still the magic number for pharmacy benefit managers (PBMs). Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years. All rights reserved. This Feed is for personal non-commercial use only.
In Drug Channels Institute’s list of the top 15 pharmacies of 2022 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.
The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). pharmacy industry—function as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. It was meant to be part of patient care.” Fein, Ph.D.,
In the video excerpt below, I walk through a brief history of 340B contract pharmacies. In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I conclude with a “follow the dollar” example of 340B prescription economics with contract pharmacies. Click here if you can’t see the video below.
As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. Below, I review key findings on the economics and operations of these specialty pharmacies.
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. million people.
In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr. Glaucomflecken helps UnitedHealthcare celebrate Doctors’ Day! d/b/a Drug Channels Institute.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook This event will be broadcast live on Friday, March 31, 2023, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.
In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. d/b/a Drug Channels Institute. P.S. Join my nearly 30,000 (!) to 1:30 p.m.
When you head to the pharmacy to pick up medicine, you likely aren’t thinking about all the steps it had to take to get into your hands — but did you know that on average, it takes about ten years for a new medication to make it to market ?
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. The rise of discount card pricing within pharmacy benefit plans is a positive development. d/b/a Drug Channels Institute. Links below.
In Medicare Part D in 2024: The Seven Largest Companies' Preferred Pharmacy Networks and the Coming Collapse of the PDP Market , I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans.
The rise of discount card pricing within pharmacy benefit plans is a positive development. Patients get access to market prices that can be lower than their PBM’s contracted rate. I’ll cover what’s next for PBMs and discount cards during my upcoming live video webinar, Drug Channels Outlook 2023 , on December 16, 2022, from 12:00 p.m.
Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *. Drug Channels, or any of its employees.
Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.
Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacymarket, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. The namesake of my alma mater once said: “Sunlight is said to be the best of disinfectants.”
In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! to 1:30 p.m.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network. d/b/a Drug Channels Institute.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. The highly-consolidated PBM market notched another year of increased concentration. Significant business relationships among the largest companies continue to shift market share.
As the market for patient-paid prescriptions has expanded, disputes about the appropriate split of these spreads will pressure pharmacy-PBM relationships and drive change in the discount card business model. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
Looks like pharmacy and PBM profiteering within the 340B Drug Pricing Program will never go out of style. Drug Channels Institute’s (DCI) latest analysis reveals that more than 33,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. to 1:30 p.m. WHAT YOU WILL LEARN Join industry expert Adam J.
Drug Channels Institutes (DCIs) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Click here to share your thoughts with the Drug Channels LinkedIn community.
This blog post explores the importance of screen reader compatibility in pharmacies, provides practical examples, and discusses why it matters for drug companies’ web pages and mobile applications. This inclusivity is fundamental to providing a positive and equitable customer experience.
In a previous article , I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Plans from Aetna, Humana, WellCare, and UnitedHealthcare will not have any independent pharmacies participating via PSAOs as preferred pharmacies. Look out below!
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content